Indications for Methotrexate Tablets:
Management of adults with severe, active rheumatoid arthritis (RA) or children with active polyarticular juvenile idiopathic arthritis (pJIA), who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose NSAIDs.
Initially 7.5mg as a single dose once weekly, or a course of three 2.5mg doses at 12-hr intervals once weekly; max 20mg/week. May give test dose first.
<2yrs: not established. ≥2yrs: initially 10mg/m2 once weekly; max 20mg/m2 per week.
Alcoholism. Chronic liver disease. Immunodeficiency. Blood dyscrasias. Pregnancy (Cat.X). Nursing mothers.
Should be used only by experienced physicians. Patients should be informed of the risks involved and be under a physician's care throughout therapy. Severe toxic reactions. Deaths have been reported. See full labeling.
Be fully familiar with this drug's toxicity before use. Discontinue if malignant lymphomas occur. Obtain baseline and monitor CBCs with differential, platelet counts, chest X-ray, and hepatic, renal and pulmonary function. During therapy monitor hematology monthly, renal and hepatic function every 1–2 months, more often if increasing dose or predisposed to toxicity (eg, dehydration). Discontinue immediately if blood counts drop significantly. Rule out pregnancy in women of childbearing potential; use effective contraception during therapy and for at least 1 ovulatory cycle afterwards for women and for at least 3 months afterwards for men. Interrupt therapy if vomiting, diarrhea, stomatitis, or pulmonary symptoms occur. Hepatic or renal impairment. Obesity. Diabetes. Peptic ulcer. Ulcerative colitis. Infection. Dehydration. Folate deficiency. Ascites, pleural effusions: evacuate fluid, monitor for toxicity and reduce dose or discontinue if needed. Elderly (use low doses and monitor closely). Debilitated.
DMARD (folic acid antagonist).
Avoid other hepatotoxic drugs, live virus vaccines. Caution with nephrotoxic agents. Toxicity increased by NSAIDs, salicylates, phenytoin, sulfonylureas, sulfonamides, probenecid, penicillins (monitor), tetracyclines, chloramphenicol, non-absorbable broad spectrum antibiotics, folic acid antagonists. Impaired response to immunization. May potentiate theophylline. Antagonized by folic acid. Radiotherapy increases risk of soft tissue necrosis, osteonecrosis. Recall reactions after UV radiation.
Elevated liver enzymes, nausea, vomiting, stomatitis, thrombocytopenia, rash, pruritus, dermatitis, diarrhea, alopecia, leukopenia, pancytopenia, dizziness, hepatoxicity, bone marrow suppression, GI toxicity, fibrosis, cirrhosis, tumor lysis syndrome, fatal skin reactions, opportunistic infections, cough, chest lesions.
Formerly known under the brand name Rheumatrex.